Stockreport

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract...

Oculis Holding AG  (OCS) 
PDF topline readout from the second Phase 3 OPTIMIZE-2 is anticipated later this year to support NDA submission If approved, OCS-01 would be the first once-daily, topical, [Read more]